The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
About this episode
Allan Shaw discusses the unpredictability of FDA decision-making and its impact on biotech.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, five-time public company CFO and seven-time public company board member Allan Shaw talks about why FDA decision-making feels less predictable, and how that uncertainty is reshaping clinical trial strategy, investor behavior, and the innovation ecosystem. We talk about FDA politicization concerns, modernization efforts like AI initiatives, and what biotech leaders can do to manage risk in...
More episodes of Business Of Biotech
- Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
- Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
- Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
- Investing In Early-Stage Oncology With Yosemite's Dan McHugh
- Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
- Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.